๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Active, closed
Impact of Intraoperative Blood Pressure Components on Postoperative AKI: A Phenotype-Stratified Analysis
NCT07156474Postoperative Acute Kidney Injury, Intraoperative Hypotension
Lanyue Zhu
Observational
44,504
Nanjing
2025-09-09
Recruiting
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
NCT07139873Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 3
250
Nanjing, Tianjin
2025-09-08
Recruiting
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NCT07099430Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
200
Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan, Shanghai
2025-09-05
Recruiting
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
NCT07082179NSCLC
Jiangsu Cancer Institute & Hospital
Phase 2
33
Nanjing
2025-09-04
Recruiting
QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
NCT07110064Advance Pancreatic Cancer
Du Juan
Phase 2
80
Nanjing
2025-09-03
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong
2025-09-02
Not yet open
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged โ‰ฅ50 Years in China
NCT07075029Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Recruiting
Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy
NCT07294859Nephrectomy, Renal Cell Cancer, AKI - Acute Kidney Injury
Jinling Hospital, China
Observational
285
Nanjing
2025-09-01
Not yet open
Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
NCT07135297Lung Cancer (Diagnosis)
Shanghai Chest Hospital
Not applicable
465
Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai
2025-09-01
Recruiting
Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions
NCT07093788PCI, Coronary Arterial Disease (CAD), Calcified Coronary Lesions
Nanjing First Hospital, Nanjing Medical University
Not applicable
78
Lianyungang, Nanjing, Yixing
2025-09-01
Active, closed
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
NCT07300488HCC
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Phase 2/3
60
Nanjing
2025-09-01
Not yet open
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
NCT07050524Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2025-09-01
Not yet open
Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection
NCT06986512Rapid Detection, Pseudomonas Aeruginosa Infection
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2025-09-01
Recruiting
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194Large B-cell Lymphoma, TP53
The First Affiliated Hospital with Nanjing Medical University
Phase 2
24
Nanjing
2025-09-01
Not yet open
Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.
NCT07105956Alzheimer's Disease (AD)
Nanjing First Hospital, Nanjing Medical University
Observational
8
Nanjing
2025-09-01
Recruiting
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
NCT07718490Metastatic Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
43
Nanjing
2025-09-01
Not yet open
Study on Proteomic and Microbiome Changes in Patients With Hepatic Encephalopathy (HE)
NCT07150195Cirrhoses, Liver, Hepatic Encephalopathy (HE)
The First Affiliated Hospital with Nanjing Medical University
Observational
32
Nanjing
2025-09
Not yet open
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
NCT06925555EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin
The First Affiliated Hospital with Nanjing Medical University
Phase 2
25
Nanjing
2025-09
Not yet open
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
NCT07131150Idiopathic Pulmonary Fibrosis (IPF)
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
By invitation
Diagnostic Application of AI-ROSE in Severe Pneumonia
NCT07113951Severe Pneumonia, Bacterial Infections
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2025-08-31
Not yet open
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
NCT07113964Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University
Phase 2
79
Nanjing
2025-08-30
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
LineMatrixยฎ Biological Vascular Graft for the Creation of Arteriovenous Graft
NCT07773051Arteriovenous Graft
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
Phase 3
180
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang
2025-08-21
Recruiting
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
NCT07105735Autoimmune Diseases Refractory to Standard Therapies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
18
Nanjing
2025-08-15
Not yet open
Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas
NCT07129499Colorectal Adenoma, High Risk, TCM
Jiangsu Famous Medical Technology Co., Ltd.
Not applicable
450
Nanjing
2025-08-15
Recruiting
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)
Sun Yat-sen University
Phase 3
386
Guangzhou, Guilin, Sanya, Changsha, Nanjing
2025-08-15
Not yet open
Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas
NCT07123116Colorectal Adenoma, TCM, Low Risk
Jiangsu Famous Medical Technology Co., Ltd.
Not applicable
450
Nanjing
2025-08-15
Recruiting
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
NCT07208981Marginal Zone Lymphoma(MZL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
169
Nanjing
2025-08-14
Recruiting
Clinical Performance Evaluation of a Diagnostic Ultrasound System
NCT07066449Echocardiography
GE Healthcare
Observational
60
Nanjing
2025-08-12
Not yet open
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07131501Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-08-11
Recruiting
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease
NCT07031531Premature Coronary Heart Disease
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
China Colorectal Cancer Screening Trial 1 (C-Cost1)
NCT07090291Colorectal Cancer, Advanced Adenoma
Zhejiang University
Not applicable
60,300
Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang
2025-08-08
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Hefei, Fuzhou, Guangzhou, Baoding, Wuhan, Changsha, Nanjing, Dalian
2025-08-05
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase 1
40
Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai
2025-08-04
Recruiting
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis
NCT07696351Deep Infiltrating Endometriosis (DIE), Infertility
Li-jun Ding
Phase 4
120
Nanjing
2025-08-01
Not yet open
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
NCT07101627Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
149
Nanjing, Shanghai
2025-08-01
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Recruiting
AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
NCT07250347Gastric Cancer Stage, Gastric Cancer Patients Undergoing Gastrectomy
The First Affiliated Hospital with Nanjing Medical University
Observational
8,000
Nanjing
2025-08-01
Not yet open
Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions๏ผˆEXIT-SEP REAL๏ผ‰
NCT07069894Sepsis
Southeast University, China
Observational
5,400
Nanjing
2025-08-01
Not yet open
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM), Plasmablastic Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1
27
Nanjing
2025-08
Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Shengyang, Jinan
2025-07-30
Recruiting
Laser-assisted Ultrasound-guided Peripheral Vein Cannulation in Cardiac Surgery
NCT07079904Ultrasonography, Interventional
Nanjing First Hospital, Nanjing Medical University
Not applicable
100
Nanjing
2025-07-24
Active, closed
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
NCT07142161Type 1 Diabetes
Nanjing Bioheng Biotech Co., Ltd.
Phase EARLY_PHASE1
3
Nanjing
2025-07-20
Not yet open
The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery
NCT07066111Postoperative Delirium
Nanjing First Hospital, Nanjing Medical University
Phase 4
40
Nanjing
2025-07-20
Recruiting
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer๏ผša Phase II Study
NCT07093866mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
20
Nanjing
2025-07-20
Not yet open
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
NCT06977828NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2025-07-20
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Not yet open
Outcomes of Sepsis Patients in China (CHINA-SEP)
NCT07066553Sepsis
Southeast University, China
Observational
5,775
Nanjing
2025-07-18
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Recruiting
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07039669Pulmonary Disease, Chronic Obstructive (COPD)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
594
Beijing, Shenzhen, Nanjing, Hangzhou
2025-07-16
Active, closed
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
NCT06963710Chronic Hepatitis B Infection
Aligos Therapeutics
Phase 2
200
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai
2025-07-15
Recruiting
Therapeutic Effect of Electroacupuncture at Zusanli (ST-36) on Diabetic Foot Wounds
NCT07482137Diabetes Foot Care
Zhongda Hospital
Not applicable
76
Nanjing
2025-07-15
Recruiting
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naรฏve Advanced Stage Follicular Lymphoma
NCT07126678Follicular Lymphoma, Treatment Naive
The First Affiliated Hospital with Nanjing Medical University
Not applicable
15
Nanjing
2025-07-15
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangzhou, Shenzhen, Changsha, Baotou, Nanjing
2025-07-15
Active, closed
Application of Pericapsular Nerve Group (PENG) Block
NCT07078773TURBT
Nanjing First Hospital, Nanjing Medical University
Not applicable
68
Nanjing
2025-07-12
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
Bristol-Myers Squibb
Phase 3
426
Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai
2025-07-10
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
Recruiting
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
NCT07309211SCLC, Limited Stage
The First Affiliated Hospital with Nanjing Medical University
Observational
25
Jinan, Nanjing, Qingdao
2025-07-08
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
Sanofi
Phase 2
99
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Recruiting
Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China
NCT07025304Nasal Obstruction Due to Inferior Turbinate Hypertrophy
Smith & Nephew, Inc.
Not applicable
105
Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou
2025-07-02
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients
NCT07030166Kidney Injury, Acute
Lanyue Zhu
Observational
10,000
Nanjing
2025-07-01
By invitation
Temporal Transformation Mechanism and Intervention Strategies of Frail-related Dietary Behaviors in Older Gastric Cancer Survivors
NCT07176455Gastric Cancer (GC), Frailty in Adult Surgery
Nanjing Medical University
Observational
438
Nanjing
2025-07-01
Active, closed
A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors
NCT07362264Liver Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1
50
Nanjing
2025-07-01
Not yet open
AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study
NCT07005791Lung Cancer (NSCLC), Leptomeningeal Metastasis, Intracranial Pressure
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
142
Nanjing
2025-07-01
Not yet open
Precision OSA Therapy Based on Phenotypes and Endotypes
NCT06825923Obstructive Sleep Apnea
Nanjing Medical University
Observational
200
Nanjing
2025-07-01
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
The Relationship Between Preoperative Frailty and Postoperative AKI and the Mediating Effect of Intraoperative BP
NCT07030179Postoperative Acute Kidney Injury, Frailty
Lanyue Zhu
Observational
1,000
Nanjing
2025-07-01
Not yet open
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
NCT06779318Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 4
464
Nanjing
2025-07
Active, closed
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
NCT06973304Short Bowel Syndrome
Takeda
Phase 3
13
Changping, Dongcheng, Nanjing, Siming
2025-06-26
Not yet open
A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)
NCT06895460Bronchial Asthma
The First Affiliated Hospital with Nanjing Medical University
Phase 3
198
Nanjing
2025-06-20
Active, closed
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
NCT06949137Osteoporosis in Post-menopausal Women, Osteoporosis
HELP Therapeutics Co., Ltd.
Phase 1
9
Nanjing
2025-06-20
Recruiting
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
NCT06992713Advanced Solid Tumor
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1
36
Nanjing, Beijing, Shanghai
2025-06-18
Active, closed
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
NCT07000955Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
98
Nanjing
2025-06-17
Not yet open
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
NCT06848439Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy, Molecular Targeted Therapy
Jiangsu Cancer Institute & Hospital
Phase 2
26
Nanjing
2025-06-15
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM
NCT07050381Arteriovenous Malformation of Central Nervous System, Aneurysm, Ruptured, Aneurysmatic Subarachnoid Haemorrhage, Aneurysm Cerebral
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2025-06-13
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Recruiting
Epidemiological Investigation of Central Venous Catheter-related Bloodstream Infections in Icus in China
NCT07255105CLABSI - Central Line Associated Bloodstream Infection
Jianfeng Xie
Observational
1,846
Nanjing
2025-06-08
Recruiting
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
NCT06830889HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
1,450
Nanjing, Shanghai
2025-06-03
Recruiting
AI-Assisted MRE for Intestinal Fibrosis in Crohn's Disease
NCT06858553Crohn Disease (CD)
Minhu Chen
Observational
234
Guangzhou, Nanjing, Huangpu, Hangzhou
2025-06-03
Active, closed
The Selection of Initial Treatment Regimens for Adolescent Nephrotic Syndrome.
NCT07071597Nephrotic Syndrome, Adolescent, Biopsy
Nanjing Children's Hospital
Observational
400
Nanjing
2025-06-01
Recruiting
Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery
NCT06942689Optimal Volume of Liposomal Bupivacaine
Nanjing First Hospital, Nanjing Medical University
Phase 4
80
Nanjing
2025-06-01
Recruiting
Application of the "Off-Clamp And Sutureless" Technique in Robot-Assisted Partial Nephrectomy
NCT07141225Renal and Urinary Disorders, Renal Cancer, Renal Particial
Shao Pengfei
Not applicable
190
Nanjing
2025-06-01
Recruiting
Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients๏ผˆGROW-ICAS๏ผ‰
NCT07085299Intracranial Artery Stenosis
Nanjing First Hospital, Nanjing Medical University
Observational
500
Nanjing
2025-06-01
Not yet open
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
NCT06901492PSMA PET/CT, Prostate Cancer, MpMRI
Nanjing First Hospital, Nanjing Medical University
Not applicable
120
Nanjing
2025-06-01
Not yet open
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naรฏve Patients With Helicobacter Pylori Infection
NCT07012785H. Pylori Infection
Zhongda Hospital
Not applicable
208
Nanjing
2025-06
Not yet open
Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting
NCT07028775Ischemic Stroke
Nanjing First Hospital, Nanjing Medical University
Observational
839
Nanjing
2025-06
Not yet open
PFA-based Bi-atrial Maze-like Catheter Ablation for PeAF
NCT06952023Atrial Fibrillation, Persistent Atrial Fibrillation
The First Affiliated Hospital of Dalian Medical University
Not applicable
390
Nanjing, Dalian, Ningbo
2025-06
Recruiting
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets
NCT07023172Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
3,000
Xinyang, Nanjing
2025-05-30
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Active, closed
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
NCT07032597Mid Face Volume Deficit
AbbVie
Phase 3
252
Beijing, Wuhan, Nanjing, Wuxi, Shanghai, Hangzhou
2025-05-26
Recruiting
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
NCT06943677Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan
2025-05-26
Rows per page Showing 401–500 of 1193
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.